Search

Your search keyword '"Kullberg, Bart-Jan"' showing total 1,131 results
Start Over Author "Kullberg, Bart-Jan"
1,131 results on '"Kullberg, Bart-Jan"'

155. Delayed clearance of intraabdominal abscesses caused by Candida albicans in tumor necrosis factor-[alpha] and lymphotoxin-[alpha]-deficient mice

Author

Vonk, Alieke G., Netea, Mihai G., Krieken, Johan H. van, Meer, Jos W.M. van der, and Kullberg, Bart Jan

Subjects
Tumor necrosis factor -- Evaluation, Tumor necrosis factor -- Research, Candida -- Physiological aspects, Candida -- Research, Infection -- Physiological aspects, Infection -- Research, Mice as laboratory animals -- Usage, Health
Published
2002

156. The role of endogenous interleukin (IL)-18, IL-12, IL-1[beta], and tumor necrosis factor-[alpha] in the production of interferon-[gamma] induced by Candida albicans in human whole-blood cultures

Author

Netea, Mihai G., Stuyt, Rogier J.L., Kim, Soo-Hyun, Van Der Meer, Jos W.M., Kullberg, Bart Jan, and Dinarello, Charles A.

Subjects
Interleukin-12 -- Physiological aspects, Interleukin-18 -- Physiological aspects, Interleukin-1 -- Physiological aspects, Candidiasis -- Physiological aspects, Disease susceptibility -- Physiological aspects, Health
Published
2002

157. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

Author

Cordonnier, Catherine, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Peter Donnelly, J., Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stephane, Maertens, Johan, Agrawal, Samir, Kibbler, Christopher, Pagliuca, Antonio, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart-Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, Malgorzata, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi-Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Department of Haematology, Oncoematologia Pediatrica, Policlinico G. B. Rossi, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Radboud university [Nijmegen], Université Sorbonne Paris Cité (USPC), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Lausanne University Hospital, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Department of Hematology, University Hospital Gasthuisberg, The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer. The ECIL-6 meeting was supported by unrestricted educational grants from Basilea, Gilead Sciences, Merck, and Pfizer, on behalf of the Fifth European Conference on Infections in Leukemia (ECIL-5†), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and The European Leukemia Net (ELN) (61 collabrators), Radboud University [Nijmegen], University Hospital Gasthuisberg [Leuven], Julius-Maximilians-Universität Würzburg (JMU), and Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Antifungal Agents, [SDV]Life Sciences [q-bio], medicine.medical_treatment, 030106 microbiology, Disease, Hematopoietic stem cell transplantation, Pneumocystis carinii, Chemoprevention, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Immunocompromised Host, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Pneumocystis jirovecii, Pharmacology (medical), Intensive care medicine, Hematologic Neoplasms, Pneumonia, Pneumocystis, Stem Cell Transplantation, Transplant Recipients, Pharmacology, Infectious Diseases, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Hematology, biology, Pneumocystis, business.industry, Mortality rate, Pneumonia, biology.organism_classification, medicine.disease, Penumocytis pneumonia, 3. Good health, Leukemia, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], 030220 oncology & carcinogenesis, immunocomrpomised host, Pnemocystis jirovecii, Stem cell, immunocomrpomised host, Penumocytis pneumonia, Pnemocystis jirovecii, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Contains fulltext : 171209.pdf (Publisher’s version ) (Closed access) Pneumocystis jirovecii can cause life-threatening pneumonia following treatment for haematological malignancies or after HSCT. The mortality rate of P. jirovecii pneumonia (PCP) in these patients is 30%-60%, especially after HSCT. The clinical presentation of PCP in haematology differs from that associated with HIV infection, with the disease being acute and more often severe, having a lower fungal burden and being more frequently linked to treatment with corticosteroids. Most cases occur in patients not receiving adequate prophylaxis. The development of new therapies, including targeted treatments and monoclonal antibodies in various haematological diseases, justifies constant vigilance in order to identify new at-risk populations and give prophylaxis accordingly. The fifth and sixth European Conferences on Infections in Leukaemia (ECIL-5 and ECIL-6) aimed to review risk factors for PCP in haematology patients and to establish evidence-based recommendations for PCP diagnosis, prophylaxis and treatment. This article focuses on the magnitude of the problem, the main differences in clinical presentation between haematology patients and other immunocompromised populations, especially HIV-infected patients, and the main risk factors.

Published
2016

161. Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study

Author

Ham, Janneke C., primary, Driessen, Chantal M., additional, Hendriks, Mathijs P., additional, Fiets, Edward, additional, Kreike, Bas, additional, Hoeben, Ann, additional, Slingerland, Marije, additional, van Opstal, Claudia C., additional, Kullberg, Bart Jan, additional, Jonker, Marianne A., additional, Adang, Eddy M., additional, Kaanders, Johannes H., additional, van der Graaf, Winette T., additional, and van Herpen, Carla M., additional

Published
2019
Full Text
View/download PDF

162. A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans

Author

Jaeger, Martin, primary, Matzaraki, Vasiliki, additional, Aguirre-Gamboa, Raúl, additional, Gresnigt, Mark S, additional, Chu, Xiaojing, additional, Johnson, Melissa D, additional, Oosting, Marije, additional, Smeekens, Sanne P, additional, Withoff, Sebo, additional, Jonkers, Iris, additional, Perfect, John R, additional, van de Veerdonk, Frank L, additional, Kullberg, Bart-Jan, additional, Joosten, Leo A B, additional, Li, Yang, additional, Wijmenga, Cisca, additional, Netea, Mihai G, additional, and Kumar, Vinod, additional

Published
2019
Full Text
View/download PDF

163. Prevalence and determinants of persistent symptoms after treatment for Lyme borreliosis: study protocol for an observational, prospective cohort study (LymeProspect)

Author

Vrijmoeth, Hedwig D., primary, Ursinus, Jeanine, additional, Harms, Margriet G., additional, Zomer, Tizza P., additional, Gauw, Stefanie A., additional, Tulen, Anna D., additional, Kremer, Kristin, additional, Sprong, Hein, additional, Knoop, Hans, additional, Vermeeren, Yolande M., additional, van Kooten, Barend, additional, Joosten, Leo A. B., additional, Kullberg, Bart-Jan, additional, Hovius, Joppe W. R., additional, and van den Wijngaard, Cees C., additional

Published
2019
Full Text
View/download PDF

166. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial

Author

Kullberg, Bart Jan, primary, Viscoli, Claudio, additional, Pappas, Peter G, additional, Vazquez, Jose, additional, Ostrosky-Zeichner, Luis, additional, Rotstein, Coleman, additional, Sobel, Jack D, additional, Herbrecht, Raoul, additional, Rahav, Galia, additional, Jaruratanasirikul, Sutep, additional, Chetchotisakd, Ploenchan, additional, Van Wijngaerden, Eric, additional, De Waele, Jan, additional, Lademacher, Christopher, additional, Engelhardt, Marc, additional, Kovanda, Laura, additional, Croos-Dabrera, Rodney, additional, Fredericks, Christine, additional, and Thompson, George R, additional

Published
2018
Full Text
View/download PDF

171. Reply to Kontoyiannis

Author

Pappas, Peter G., Kauffman, Carol A., Calandra, Thierry F., Kullberg, Bart-Jan, and Sobel, Jack D.

Published
2017

172. Antibiotic research and development: business as usual?

Author

Harbarth, S., Theuretzbacher, U., Hackett, J., Adriaenssens, Niels, Anderson, James, Antonisse, Ad, Årdal, Christine, Baillon-Plot, Nathalie, Baraldi, Enrico, Bettiol, Esther, Bhatti, Taimur, Bradshaw, David, Brown, Nicholas, Carmeli, Yehuda, Cars, Otto, Charbonneau, Claudie, Cheng, Sue, Ciabuschi, Francesco, Cirino, Joseph, Clift, Charles, Colson, Abby, Dane, Aaron, De-Lima, Natalie, Dooa, Mindy, Drabik, Dusan, Eisenstein, Barry, Farquhar, Ronald, Fidan, Dogan, Findlay, David, Galli, Frederic, Gilchrist, Kim, Gilman, Steve, Goeschl, Timo, Goodall, Jonathan, Goossens, Herman, Gouglas, Dimitrios, Guise, Tracey, Gyssens, Inge, Hallerbäck, Peter, Heymann, David, Hoffman, Steven, Howell, Jenny, Hulscher, Marlies, Hunt, Timothy, Huttner, Benedikt, Jantarada, Fabricio, Jaquest, Dominique, Joly, Florence, Ka, Lum, Karas, Andreas, Knirsch, Charles, Kullberg, Bart-Jan, Laxminarayan, Ramanan, Le Maréchal, Marion, Legros, Stéphane, Lilliott, Nicky, Lindgren, Eva, Longshaw, Chris, Mahoney, Nicole, Mastrangelo, Dana, McDonald, John, McKeever, Steve, Mepham, Tim, Milanic, Romina, Monnier, Annelie, Morel, Chantal, Morton, Alec, Mossialos, Elias, Nolet, Brigitte, Outterson, Kevin, Payne, David, Piddock, Laura, Plahte, Jens, Potter, Danielle, Pulcini, Céline, Rex, John, Ross, Emma, Rottingen, John-Arne, Ryan, Kellie, Ryan, James, Salimi, Tehseen, Schouten, Jeroen, Schultz, Suzanne, So, Antony, Spiesser, Julie, Stålhammar, Nils-Olov, Stanic, Mirji, Tacconelli, Evelina, Temkin, Liz, Trick, Donald, Vink, Patrick, Vlahovic-Palcevski, Vera, Watt, Maureen, Wells, Marc, Wesseler, Justus, White, Alex, Wood, Susan, Zanichelli, Veronica, and Zorzet, Anna

Abstract

This article contends that poor economic incentives are an important reason for the lack of new drugs and explains how the DRIVE-AB intends to change the landscape by harnessing the expertise, motivation and diversity of its partners

Published
2017

173. still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response

Author

Cordonnier, Catherine, Alanio, Alexandre, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J.G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stephane, Maertens, Johan, Agrawal, Samir, Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Berg, Thomas, Blennow, Ola, Bruggemann, Roger, Calandra, Thierry, Castagnola, Elio, Cornely, Oliver, De La Camara, Rafael, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Girmenia, Corrado, Hargreaves, Ruth, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Petr, Kibbler, Christopher, Klyasova, Galina, Kouba, Michal, Kullberg, Bart Jan, Ljungman, Per, Mallet, Vincent, Marchetti, Oscar, Mikulska, Malgorzata, Munoz, Patricia, Orasch, Christina, Pagano, Livio, Pagliuca, Antonio, Penack, Olaf, Pettrikos, George, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valerie, Roilides, Emmanuel, on behalf of the Fifth European Conference on Infections in Leukemia (ECIL-5), The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN), Instituto de Higiene e Medicina Tropical (IHMT), Global Health and Tropical Medicine (GHTM), and TB, HIV and opportunistic diseases and pathogens (THOP)

Subjects
Carinii-pneumonia, Aids, Infectious Diseases, ECIL guidelines, SDG 3 - Good Health and Well-being, Outbreaks, Infection, Infants, Management
Abstract

Made available in DSpace on 2021-09-24T00:56:32Z (GMT). No. of bitstreams: 0 Previous issue date: 2017-04-01 publishersversion published

Published
2017

174. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response

Author

Cordonnier, Catherine, Alanio, Alexandre, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stéphane, Maertens, Johan, Agrawal, Samir, Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Berg, Thomas, Blennow, Ola, Brüggemann, Roger, Calandra, Thierry, Castagnola, Elio, Cornely, Oliver, De La Camara, Rafael, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Girmenia, Corrado, Hargreaves, Ruth, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Petr, Kibbler, Christopher, Klyasova, Galina, Kouba, Michal, Kullberg, Bart-Jan, Ljungman, Per, Mallet, Vincent, Marchetti, Oscar, Mikulska, Malgorzata, Munoz, Patricia, Orasch, Christina, Pagano, Livio, Pagliuca, Antonio, Penack, Olaf, Pettrikos, George, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valérie, Roilides, Emmanuel, Sinko, Janos, Skiada, Anna, Slavin, Monica, Styczynski, Jan, Tissot, Frederic, Tweddle, Lorraine, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Viscoli, Claudio, Ward, Katherine, and Wood, Craig

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, 030106 microbiology, HIV Infections, Pneumocystis carinii, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Hematologic Neoplasms, Humans, Pneumonia, Pneumocystis, Stem Cell Transplantation, Pharmacology, Pharmacology (medical), Infectious Diseases, Medicine, In patient, Intensive care medicine, hematopoietic stem cell transplant, business.industry, Pneumocystis, PNEUMOCYSTIS JIROVECI, Pneumocystis jiroveci, infection, hematopoietic stem cell transplant, Pneumocystis jirovecii Pneumonia, Pneumocystis jiroveci, Pneumonia, medicine.disease, infection, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Stem cell, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Contains fulltext : 169784.pdf (Publisher’s version ) (Closed access)

Published
2017

177. Quality Indicators for Appropriate Outpatient Parenteral Antimicrobial Therapy in Adults: A Systematic Review and RAND-modified Delphi Procedure.

Author

Berrevoets, Marvin A H, Oever, Jaap ten, Oerlemans, Anke J M, Kullberg, Bart Jan, Hulscher, Marlies E, and Schouten, Jeroen A

Subjects
ANTI-infective agents, CLINICAL medicine, DELPHI method, INTRAVENOUS therapy, QUALITY assurance, SYSTEMATIC reviews, KEY performance indicators (Management), PARENTERAL infusions, ADULTS
Abstract

Background Our aim in this study was to develop quality indicators (QIs) for outpatient parenteral antimicrobial therapy (OPAT) care that can be used as metrics for quality assessment and improvement. Methods A RAND-modified Delphi procedure was used to develop a set of QIs. Recommendations on appropriate OPAT care in adults were retrieved from the literature using a systematic review and translated into potential QIs. These QIs were appraised and prioritized by a multidisciplinary panel of international OPAT experts in 2 questionnaire rounds combined with a meeting between rounds. Results The procedure resulted in 33 OPAT-specific recommendations. The following QIs that describe recommended OPAT care were prioritized by the expert panel: the presence of a structured OPAT program, a formal OPAT care team, a policy on patient selection criteria, and a treatment and monitoring plan; assessment for OPAT should be performed by the OPAT team; patients and family should be informed about OPAT; there should be a mechanism in place for urgent discussion and review of emergent clinical problems, and a system in place for rapid communication; laboratory results should be delivered to physicians within 24 hours; and the OPAT team should document clinical response to antimicrobial management, document adverse events, and monitor QIs for OPAT care and make these data available. Conclusions We systematically developed a set of 33 QIs for optimal OPAT care, of which 12 were prioritized by the expert panel. These QIs can be used to assess and improve the quality of care provided by OPAT teams. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

178. Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease

Author

Berende, Anneleen, primary, Nieuwenhuis, Lisette, additional, ter Hofstede, Hadewych J. M., additional, Vos, Fidel J., additional, Vogelaar, Michiel L., additional, Tromp, Mirjam, additional, van Middendorp, Henriët, additional, Donders, A. Rogier T., additional, Evers, Andrea W. M., additional, Kullberg, Bart Jan, additional, and Adang, Eddy M. M., additional

Published
2018
Full Text
View/download PDF

179. Neutrophils differentially attenuate immune response toAspergillusinfection through complement receptor 3 and induction of myeloperoxidase

Author

Goh, Jessamine G., primary, Ravikumar, Sharada, additional, Win, Mar Soe, additional, Cao, Qiong, additional, Tan, Ai Ling, additional, Lim, Joan H. J., additional, Leong, Winnie, additional, Herbrecht, Raoul, additional, Troke, Peter F., additional, Kullberg, Bart Jan, additional, Netea, Mihai G., additional, Chng, Wee Joo, additional, Dan, Yock Young, additional, and Chai, Louis Y. A., additional

Published
2017
Full Text
View/download PDF

184. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author

Maertens, Johan, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stã©phane, Cordonnier, Catherine, Agrawal, Samir, Kibbler, Christopher, Pagliuca, SIMONE ANTONIO, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart-Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, Malgorzata, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi-Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Department of Hematology, University Hospital Gasthuisberg, G.B. Rossi Hospital, Verona University, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Radboud university [Nijmegen], Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Lausanne University Hospital, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer., University Hospital Gasthuisberg [Leuven], Università degli studi di Verona = University of Verona (UNIVR), Radboud University [Nijmegen], Julius-Maximilians-Universität Würzburg (JMU), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)

Subjects
0301 basic medicine, Microbiology (medical), Antifungal Agents, [SDV]Life Sciences [q-bio], 030106 microbiology, Pneumocitis jirovecii, Chemoprevention, Trimethoprim, Immunocompromised Host, 03 medical and health sciences, 0302 clinical medicine, Trimethoprim, Sulfamethoxazole Drug Combination, Humans, Pharmacology (medical), Pharmacology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Sulfamethoxazole Drug Combination, Pneumocystis, Hematologic Neoplasms, Pneumonia, Pneumocystis, Stem Cell Transplantation, Transplant Recipients, Infectious Diseases, immunocomrpomised host, pneumonia, Pneumocitis jirovecii, Pneumonia, 3. Good health, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], 030220 oncology & carcinogenesis, immunocomrpomised host, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Contains fulltext : 172373.pdf (Publisher’s version ) (Closed access) The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

Published
2016

185. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author

Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg Larsen, Jannik, Matos, Olga, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Cordonnier, Catherine, Maertens, Johan, Bretagne, Stã©phane, Agrawal, Samir, Kibbler, Christopher, Pagliuca, Antonio, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, MALGORZATA KAROLINA, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire (CNRMA), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Université de Lausanne = University of Lausanne (UNIL), Université Catholique de Louvain = Catholic University of Louvain (UCL), Radboud University [Nijmegen], Rigshospitalet [Copenhagen], Copenhagen University Hospital, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Università degli studi di Verona = University of Verona (UNIVR), Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius Maximilians University Wurzburg, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Department of Hematology, University Hospital Gasthuisberg [Leuven], The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer, Université de Lausanne (UNIL), Radboud university [Nijmegen], G.B. Rossi Hospital, Verona University, University Hospital Gasthuisberg, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Julius-Maximilians-Universität Würzburg (JMU)

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, [SDV]Life Sciences [q-bio], 030106 microbiology, Dapsone, Pneumocystis carinii, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Diagnostic Tests, Internal medicine, medicine, Pneumocistis jirovecii, Humans, Routine, Pharmacology (medical), 030212 general & internal medicine, Intensive care medicine, Pharmacology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], business.industry, Diagnostic Tests, Routine, Pneumocystis, Pneumonia, Pneumocystis, Pneumonia, medicine.disease, Trimethoprim, Transplant Recipients, 3. Good health, Fludarabine, Regimen, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Hematologic Neoplasms, Alemtuzumab, Rituximab, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Pentamidine, medicine.drug, immunocompromised host, pneumonia, Pneumocistis jirovecii, Stem Cell Transplantation
Abstract

Item does not contain fulltext The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a meeting to establish evidence-based recommendations for using tests to diagnose Pneumocystis jirovecii pneumonia (PCP) in adult patients with haematological malignancies. Immunofluorescence assays are recommended as the most sensitive microscopic method (recommendation A-II: ). Real-time PCR is recommended for the routine diagnosis of PCP ( A-II: ). Bronchoalveolar lavage (BAL) fluid is recommended as the best specimen as it yields good negative predictive value ( A-II: ). Non-invasive specimens can be suitable alternatives ( B-II: ), acknowledging that PCP cannot be ruled out in case of a negative PCR result ( A-II: ). Detecting beta-d-glucan in serum can contribute to the diagnosis but not the follow-up of PCP ( A-II: ). A negative serum beta-d-glucan result can exclude PCP in a patient at risk ( A-II: ), whereas a positive test result may indicate other fungal infections. Genotyping using multilocus sequence markers can be used to investigate suspected outbreaks ( A-II: ). The routine detection of dihydropteroate synthase mutations in cases of treatment failure is not recommended ( B-II: ) since these mutations do not affect response to high-dose co-trimoxazole. The clinical utility of these diagnostic tests for the early management of PCP should be further assessed in prospective, randomized interventional studies.

Published
2016

186. AIDS-related mycoses: the way forward

Author

Brown, Gordon D, Meintjes, Graeme, Kolls, Jay K, Gray, Clive, Horsnell, William, Working Group from the EMBO-AIDS Related Mycoses Workshop, Achan, Beatrice, Alber, Gottfried, Aloisi, Maria, Armstrong-James, Darius, Beale, Mathew, Bicanic, Tihana, Black, John, Bohjanen, Paul, Botes, Angela, Boulware, David R, Brown, Gordon, Bunjun, Rubina, Carr, William, Casadevall, Arturo, Chang, Christina, Chivero, Ernest, Corcoran, Craig, Cross, Anna, Dawood, Halima, Day, Jeremy, De Bernardis, Flavia, De Jager, Veronique, De Repentigny, Louis, Denning, David, Eschke, Maria, Finkelman, Malcolm, Govender, Nelesh, Gow, Neil, Graham, Lisa, Gryschek, Ronaldo, Hammond-Aryee, Kenneth, Harrison, Tom, Heard, Neil, Hill, Melanie, Hoving, J Claire, Janoff, Edward, Jarvis, Joseph, Kayuni, Sekeleghe, King, Karin, Kolls, Jay, Kullberg, Bart-Jan, Lalloo, David G, Letang, Emilio, Levitz, Stuart, Limper, Andrew, Longley, Nicky, Machiridza, Tendai Rodney, Mahabeer, Yesholata, Martinsons, Neil, Meiring, Susan, Meya, David, Miller, Robert, Molloy, Sile, Morris, Lynn, Mukaremera, Liliane, Musubire, Abdu K, Muzoora, Conrad, Nair, Amy, Nakiwala Kimbowa, Justine, Netea, Mihai, Nielsen, Kirsten, O'hern, Jennifer, Okurut, Samuel, Parker, Arifa, Patterson, Tom, Pennap, Grace, Perfect, John, Prinsloo, Chrisna, Rhein, Joshua, Rolfes, Melissa A, Samuel, Catherine, Schutz, Charlotte, Scriven, James, Sebolai, Olihile M, Sojane, Katlego, Sriruttan, Charlotte, Stead, David, Steyn, Annica, Thawer, Narjis K, Thienemann, Friedrich, Von Hohenberg, Maximilian, Vreulink, Jo-marie, Wessels, Jeannette, Wood, Kathryn, and Yang, Yun-liang

Subjects
Microbiology (medical), medicine.medical_specialty, Medical mycology, AIDS-Related Opportunistic Infections, Human immunodeficiency virus (HIV), lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Developing country, Translational research, Biology, medicine.disease_cause, medicine.disease, Microbiology, Article, Infectious Diseases, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Acquired immunodeficiency syndrome (AIDS), Virology, Immunology, Epidemiological surveillance, medicine, Intensive care medicine
Abstract

Item does not contain fulltext The contribution of fungal infections to the morbidity and mortality of HIV-infected individuals is largely unrecognized. A recent meeting highlighted several priorities that need to be urgently addressed, including improved epidemiological surveillance, increased availability of existing diagnostics and drugs, more training in the field of medical mycology, and better funding for research and provision of treatment, particularly in developing countries.

Published
2014

188. Influenza-associated Aspergillosis in Critically Ill Patients

Author

van de Veerdonk, Frank L., primary, Kolwijck, Eva, additional, Lestrade, Pieter P. A., additional, Hodiamont, Caspar J., additional, Rijnders, Bart J. A., additional, van Paassen, Judith, additional, Haas, Pieter-Jan, additional, Oliveira dos Santos, Claudy, additional, Kampinga, Greetje A., additional, Bergmans, Dennis C. J. J., additional, van Dijk, Karin, additional, de Haan, Anton F. J., additional, van Dissel, Jaap, additional, van der Hoeven, Hans G., additional, Verweij, Paul E., additional, Rahamat-Langendoen, Janette C., additional, Kullberg, Bart-Jan, additional, Netea, Mihai G., additional, Brüggeman, Roger J., additional, Hoedemaekers, Astrid W., additional, Melchers, Willem J. G., additional, Freudenburg, Wieke, additional, Roescher, Nienke, additional, Wiersinga, W. Joost, additional, van den Berg, Charlotte H. S. B., additional, Vonk, Alieke G., additional, Tienen, Carla van, additional, Hoven, Ben van der, additional, van der Beek, Martha T., additional, Derde, Lennie P.G., additional, Leer, Coretta van, additional, Aardema, Heleen, additional, Lashof, Astrid Oude, additional, and Ang, C. Wim, additional

Published
2017
Full Text
View/download PDF

191. An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility

Author

Matzaraki, Vasiliki, primary, Gresnigt, Mark S., additional, Jaeger, Martin, additional, Ricaño-Ponce, Isis, additional, Johnson, Melissa D., additional, Oosting, Marije, additional, Franke, Lude, additional, Withoff, Sebo, additional, Perfect, John R., additional, Joosten, Leo A. B., additional, Kullberg, Bart Jan, additional, van de Veerdonk, Frank L., additional, Jonkers, Iris, additional, Li, Yang, additional, Wijmenga, Cisca, additional, Netea, Mihai G., additional, and Kumar, Vinod, additional

Published
2017
Full Text
View/download PDF

193. Cost-effectiveness of prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).

Author

Ham, Janneke, primary, Driessen, Chantal, additional, Hendriks, Mathijs P, additional, Fiets, W. Edward, additional, Kreike, Bas, additional, Hoeben, Ann, additional, Slingerland, Marije, additional, Opstal, Claudia van, additional, Kullberg, Bart-Jan, additional, Adang, Eddy MM, additional, Kaanders, Johannes, additional, Van Der Graaf, Winette T.A., additional, and Van Herpen, Carla M.L.-, additional

Published
2017
Full Text
View/download PDF

195. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials

Author

Kullberg, Bart Jan, primary, Vasquez, José, additional, Mootsikapun, Piroon, additional, Nucci, Marcio, additional, Paiva, José-Artur, additional, Garbino, Jorge, additional, Yan, Jean Li, additional, Aram, Jalal, additional, Capparella, Maria Rita, additional, Conte, Umberto, additional, Schlamm, Haran, additional, Swanson, Robert, additional, and Herbrecht, Raoul, additional

Published
2017
Full Text
View/download PDF

196. 18F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality

Author

Berrevoets, Marvin A.H., primary, Kouijzer, Ilse J.E., additional, Aarntzen, Erik H.J.G., additional, Janssen, Marcel J.R., additional, De Geus-Oei, Lioe-Fee, additional, Wertheim, Heiman F.L., additional, Kullberg, Bart-Jan, additional, Oever, Jaap Ten, additional, Oyen, Wim J.G., additional, and Bleeker-Rovers, Chantal P., additional

Published
2017
Full Text
View/download PDF

197. Functional and Genomic Architecture of Borrelia burgdorferi -Induced Cytokine Responses in Humans

Author

Oosting, Marije, primary, Kerstholt, Mariska, additional, ter Horst, Rob, additional, Li, Yang, additional, Deelen, Patrick, additional, Smeekens, Sanne, additional, Jaeger, Martin, additional, Lachmandas, Ekta, additional, Vrijmoeth, Hedwig, additional, Lupse, Mihaela, additional, Flonta, Mirela, additional, Cramer, Robert A., additional, Kullberg, Bart Jan, additional, Kumar, Vinod, additional, Xavier, Ramnik, additional, Wijmenga, Cisca, additional, Netea, Mihai G., additional, and Joosten, Leo A.B., additional

Published
2016
Full Text
View/download PDF

199. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.

Author

Kullberg, Bart Jan, Viscoli, Claudio, Pappas, Peter G, Vazquez, Jose, Ostrosky-Zeichner, Luis, Rotstein, Coleman, Sobel, Jack D, Herbrecht, Raoul, Rahav, Galia, Jaruratanasirikul, Sutep, Chetchotisakd, Ploenchan, Wijngaerden, Eric Van, Waele, Jan De, Lademacher, Christopher, Engelhardt, Marc, Kovanda, Laura, Croos-Dabrera, Rodney, Fredericks, Christine, and Thompson, George R

Subjects
*COMPARATIVE studies, *CONFIDENCE intervals, *GENERIC drug substitution, *INTRAVENOUS therapy, *ORAL drug administration, *PATIENT safety, *RANDOMIZED controlled trials, *TREATMENT effectiveness, *BLIND experiment, *CANDIDEMIA, *INVASIVE candidiasis, *VORICONAZOLE, *THERAPEUTICS
Abstract

Background Isavuconazole was compared to caspofungin followed by oral voriconazole in a Phase 3, randomized, double-blind, multinational clinical trial for the primary treatment of patients with candidemia or invasive candidiasis. Methods Adult patients were randomized 1:1 to isavuconazole (200 mg intravenous [IV] three-times-daily [TID] for 2 days, followed by 200 mg IV once-daily [OD]) or caspofungin (70 mg IV OD on day 1, followed by 50 mg IV OD [70 mg in patients > 80 kg]) for a maximum of 56 days. After day 10, patients could switch to oral isavuconazole (isavuconazole arm) or voriconazole (caspofungin arm). Primary efficacy endpoint was successful overall response at the end of IV therapy (EOIVT) in patients with proven infections who received ≥1 dose of study drug (modified-intent-to-treat [mITT] population). The pre-specified noninferiority margin was 15%. Secondary outcomes in the mITT population were successful overall response at 2 weeks after the end of treatment, all-cause mortality at days 14 and 56, and safety. Results Of 450 patients randomized, 400 comprised the mITT population. Baseline characteristics were balanced between groups. Successful overall response at EOIVT was observed in 60.3% of patients in the isavuconazole arm and 71.1% in the caspofungin arm (adjusted difference -10.8, 95% confidence interval -19.9–-1.8). The secondary endpoints, all-cause mortality, and safety were similar between arms. Median time to clearance of the bloodstream was comparable between groups. Conclusions This study did not demonstrate non-inferiority of isavuconazole to caspofungin for primary treatment of invasive candidiasis. Secondary endpoints were similar between both groups. Clinical Trials Registration NCT00413218. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

200. The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases

Author

ten Oever, Jaap Kox, Matthijs De Veerdonk, Frank L. Van and Mothapo, Khutso M. Slavcovici, Adriana Jansen, Tim L. and Tweehuysen, Lieke Giamarellos-Bourboulis, Evangelos J. and Schneeberger, Peter M. Wever, Peter C. Stoffels, Monique and Simon, Anna Van der Meer, Jos Wm Johnson, Melissa D. and Kullberg, Bart-Jan Pickkers, Peter Pachot, Alexandre Ab Joosten, Leo Netea, Mihai G.

Abstract

Background: The extracellular domains of cytokine receptors are released during inflammation, but little is known about the shedding of Toll-like receptors (TLR) and whether they can be used as diagnostic biomarkers. Methods: The release of sTLR2 and sTLR4 was studied in in-vitro stimulations, as well as in-vivo during experimental human endotoxemia (n = 11, 2 ng/kg LPS), and in plasma of 394 patients with infections (infectious mononucleosis, measles, respiratory tract infections, bacterial sepsis and candidemia) or non-infectious inflammation (Crohn’s disease, gout, rheumatoid arthritis, autoinflammatory syndromes and pancreatitis). Using C-statistics, the value of sTLR2 and sTLR4 levels for discrimination between infections and non-infectious inflammatory diseases, as well as between viral and bacterial infections was analyzed. Results: In-vitro, peripheral blood mononuclear cells released sTLR2 and sTLR4 by exposure to microbial ligands. During experimental human endotoxemia, plasma concentrations peaked after 2 hours (sTLR4) and 4 hours (sTLR2). sTLR4 did not correlate with cytokines, but sTLR2 correlated positively with TNF alpha (r(s) = 0.80, P < 0.05), IL-6 (r(s) = 0.65, P < 0.05), and IL-1Ra (r(s) = 0.57, P = 0.06), and negatively with IL-10 (r(s) = -0.58, P = 0.06), respectively. sTLR4 had a similar area under the ROC curve [AUC] for differentiating infectious and non-infectious inflammation compared to CRP: 0.72 (95% CI 0.66-0.79) versus 0.74 (95% CI 0.69-0.80) [P = 0.80], while sTLR2 had a lower AUC: 0.60 (95% CI 0.54-0.66) [P = 0.0004]. CRP differentiated bacterial infections better from viral infections than sTLR2 and sTLR4: AUC 0.94 (95% CI 0.90-0.96) versus 0.58 (95% CI 0.51-0.64) and 0.75 (95% CI 0.70-0.80), respectively [P < 0.0001 for both]. Conclusions: sTLRs are released into the circulation, and suggest the possibility to use sTLRs as diagnostic tool in inflammatory conditions.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results